vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $112.4M, roughly 1.1× BYLINE BANCORP, INC.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs 3.3%, a 30.1% gap on every dollar of revenue. On growth, BYLINE BANCORP, INC. posted the faster year-over-year revenue change (9.0% vs 4.7%). Over the past eight quarters, BYLINE BANCORP, INC.'s revenue compounded faster (6.4% CAGR vs 5.6%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
BY vs NATR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $123.8M |
| Net Profit | $37.6M | $4.1M |
| Gross Margin | — | 72.5% |
| Operating Margin | — | 4.3% |
| Net Margin | 33.4% | 3.3% |
| Revenue YoY | 9.0% | 4.7% |
| Net Profit YoY | 33.0% | 1379.4% |
| EPS (diluted) | $0.83 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $123.8M | ||
| Q3 25 | $115.7M | $128.3M | ||
| Q2 25 | $110.5M | $114.8M | ||
| Q1 25 | $103.1M | $113.2M | ||
| Q4 24 | $104.7M | $118.2M | ||
| Q3 24 | $101.8M | $114.6M | ||
| Q2 24 | $99.4M | $110.6M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $4.1M | ||
| Q3 25 | $37.2M | $5.3M | ||
| Q2 25 | $30.1M | $5.3M | ||
| Q1 25 | $28.2M | $4.7M | ||
| Q4 24 | $30.3M | $-321.0K | ||
| Q3 24 | $30.3M | $4.3M | ||
| Q2 24 | $29.7M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 73.3% | ||
| Q2 25 | — | 71.7% | ||
| Q1 25 | — | 72.1% | ||
| Q4 24 | — | 72.0% | ||
| Q3 24 | — | 71.3% | ||
| Q2 24 | — | 71.4% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 4.3% | ||
| Q3 25 | 43.1% | 7.0% | ||
| Q2 25 | 35.2% | 3.7% | ||
| Q1 25 | 36.4% | 5.4% | ||
| Q4 24 | 38.6% | 3.8% | ||
| Q3 24 | 39.3% | 4.6% | ||
| Q2 24 | 40.4% | 5.1% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | 3.3% | ||
| Q3 25 | 32.1% | 4.2% | ||
| Q2 25 | 27.2% | 4.6% | ||
| Q1 25 | 27.4% | 4.2% | ||
| Q4 24 | 34.3% | -0.3% | ||
| Q3 24 | 29.8% | 3.8% | ||
| Q2 24 | 29.9% | 1.2% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.23 | ||
| Q3 25 | $0.82 | $0.30 | ||
| Q2 25 | $0.66 | $0.28 | ||
| Q1 25 | $0.64 | $0.25 | ||
| Q4 24 | $0.68 | $-0.02 | ||
| Q3 24 | $0.69 | $0.23 | ||
| Q2 24 | $0.68 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $161.6M |
| Total Assets | $9.9B | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $93.9M | ||
| Q3 25 | $259.0M | $95.6M | ||
| Q2 25 | $218.3M | $81.3M | ||
| Q1 25 | $421.3M | $86.5M | ||
| Q4 24 | $563.1M | $84.7M | ||
| Q3 24 | $452.6M | $78.7M | ||
| Q2 24 | $730.5M | $68.7M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $161.6M | ||
| Q3 25 | $1.2B | $166.7M | ||
| Q2 25 | $1.2B | $163.7M | ||
| Q1 25 | $1.1B | $167.1M | ||
| Q4 24 | $1.1B | $161.0M | ||
| Q3 24 | $1.1B | $162.6M | ||
| Q2 24 | $1.0B | $156.4M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $261.1M | ||
| Q3 25 | $9.8B | $264.8M | ||
| Q2 25 | $9.7B | $254.9M | ||
| Q1 25 | $9.6B | $252.7M | ||
| Q4 24 | $9.5B | $240.9M | ||
| Q3 24 | $9.4B | $245.3M | ||
| Q2 24 | $9.6B | $235.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $9.9M | ||
| Q3 25 | $38.3M | $18.5M | ||
| Q2 25 | $16.3M | $4.3M | ||
| Q1 25 | $27.1M | $2.6M | ||
| Q4 24 | $175.2M | $12.2M | ||
| Q3 24 | $19.8M | $9.6M | ||
| Q2 24 | $40.1M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $7.6M | ||
| Q3 25 | $38.0M | $16.8M | ||
| Q2 25 | $15.2M | $3.0M | ||
| Q1 25 | $25.0M | $1.5M | ||
| Q4 24 | $171.2M | $10.0M | ||
| Q3 24 | $19.1M | $7.9M | ||
| Q2 24 | $39.4M | $-2.0M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 6.1% | ||
| Q3 25 | 32.8% | 13.1% | ||
| Q2 25 | 13.7% | 2.6% | ||
| Q1 25 | 24.3% | 1.3% | ||
| Q4 24 | 163.5% | 8.5% | ||
| Q3 24 | 18.8% | 6.9% | ||
| Q2 24 | 39.7% | -1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 1.9% | ||
| Q3 25 | 0.3% | 1.3% | ||
| Q2 25 | 1.0% | 1.2% | ||
| Q1 25 | 2.0% | 1.0% | ||
| Q4 24 | 3.8% | 1.9% | ||
| Q3 24 | 0.6% | 1.5% | ||
| Q2 24 | 0.7% | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 2.41× | ||
| Q3 25 | 1.03× | 3.46× | ||
| Q2 25 | 0.54× | 0.81× | ||
| Q1 25 | 0.96× | 0.55× | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | 2.21× | ||
| Q2 24 | 1.35× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
